| Oct 2 |
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
| Sep 23 |
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now
|
| Sep 23 |
UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock
|
| Sep 16 |
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
|
| Sep 5 |
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 29 |
UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector
|
| Aug 29 |
UroGen Pharma to Present at Upcoming Investor Conferences
|
| Aug 28 |
UroGen Pharma: There Is Some Potential Here
|
| Aug 16 |
UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88
|
| Aug 14 |
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
